ARVINAS, INC. Increase (Decrease) in Contract with Customer, Liability
ARVINAS, INC. (ARVN) reported Increase (Decrease) in Contract with Customer, Liability of -$205.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04
- ARVINAS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$189.90M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$15.60M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$9.50M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$21.80M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$242.60M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$101.00M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$74.60M.
- ARVINAS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$116.80M, a 116.79% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$189.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$205.50M 10-Q · filed 2026-08-04 | -$215.00M derived: sum of 3 quarters · filed 2026-08-04 | -$236.80M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$15.60M 10-Q · filed 2026-05-11 | -$25.10M derived: sum of 2 quarters · filed 2026-05-11 | -$46.90M derived: sum of 3 quarters · filed 2026-05-11 | -$69.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$31.30M derived: sum of 2 quarters · filed 2026-02-24 | -$53.70M derived: sum of 3 quarters · filed 2026-08-04 | -$242.60M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | -$21.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$44.20M derived: sum of 2 quarters · filed 2026-08-04 | -$233.10M 10-Q · filed 2025-11-05 | -$288.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$22.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$211.30M 10-Q · filed 2026-08-04 | -$266.80M derived: sum of 3 quarters · filed 2026-08-04 | -$362.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$188.90M 10-Q · filed 2026-05-11 | -$244.40M derived: sum of 2 quarters · filed 2026-05-11 | -$339.90M derived: sum of 3 quarters · filed 2026-05-11 | -$264.60M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$55.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$151.00M derived: sum of 2 quarters · filed 2026-02-24 | -$75.70M derived: sum of 3 quarters · filed 2026-02-24 | -$101.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | -$95.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$20.20M derived: sum of 2 quarters · filed 2025-11-05 | -$45.50M 10-Q · filed 2025-11-05 | -$2.40M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $75.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $50.00M 10-Q · filed 2025-08-06 | $93.10M derived: sum of 3 quarters · filed 2026-02-24 | $58.50M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | -$25.30M 10-Q · filed 2025-05-01 | $17.80M derived: sum of 2 quarters · filed 2026-02-24 | -$16.80M derived: sum of 3 quarters · filed 2026-02-24 | -$70.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $43.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.50M derived: sum of 2 quarters · filed 2026-02-24 | -$44.70M derived: sum of 3 quarters · filed 2026-02-24 | -$74.60M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | -$34.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$87.80M derived: sum of 2 quarters · filed 2024-10-30 | -$117.70M 10-Q · filed 2024-10-30 | -$151.70M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-06-30 | -$53.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | -$83.10M 10-Q · filed 2024-07-30 | -$117.10M derived: sum of 3 quarters · filed 2025-02-11 | -$147.40M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2023-03-31 | -$29.90M 10-Q · filed 2024-05-07 | -$63.90M derived: sum of 2 quarters · filed 2025-02-11 | -$94.20M derived: sum of 3 quarters · filed 2025-02-11 | -$125.50M derived: sum of 4 quarters · filed 2025-02-11 | ||||
| 2022-12-31 | -$34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | -$64.30M derived: sum of 2 quarters · filed 2025-02-11 | -$95.60M derived: sum of 3 quarters · filed 2025-02-11 | -$116.80M 10-K · filed 2025-02-11 | ||||
| 2022-09-30 | -$30.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$61.60M derived: sum of 2 quarters · filed 2023-11-07 | -$82.80M 10-Q · filed 2023-11-07 | -$105.60M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | -$31.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$52.50M 10-Q · filed 2023-08-08 | -$75.30M derived: sum of 3 quarters · filed 2024-02-27 | $651.10M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | -$21.20M 10-Q · filed 2023-05-05 | -$44.00M derived: sum of 2 quarters · filed 2024-02-27 | $682.40M derived: sum of 3 quarters · filed 2024-02-27 | $676.80M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | -$22.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $703.60M derived: sum of 2 quarters · filed 2024-02-27 | $698.00M derived: sum of 3 quarters · filed 2024-02-27 | $695.50M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $726.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $720.80M derived: sum of 2 quarters · filed 2022-11-09 | $718.30M 10-Q · filed 2022-11-09 | $718.28M 10-Q · filed 2021-11-03 | $718.10M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-06-30 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$8.10M 10-Q · filed 2022-08-04 | -$8.08M 10-Q · filed 2021-08-05 | -$8.30M derived: sum of 3 quarters · filed 2023-02-23 | -$13.45M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-03-31 | -$2.50M 10-Q · filed 2022-05-05 | -$2.54M 10-Q · filed 2021-05-04 | -$2.70M derived: sum of 2 quarters · filed 2023-02-23 | -$7.85M derived: sum of 3 quarters · filed 2023-02-23 | -$13.59M derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | -$197.05K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$5.35M derived: sum of 2 quarters · filed 2023-02-23 | -$11.09M derived: sum of 3 quarters · filed 2023-02-23 | -$13.30M 10-K · filed 2023-02-23 | -$13.32M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$10.89M derived: sum of 2 quarters · filed 2021-11-03 | -$13.10M 10-Q · filed 2021-11-03 | -$16.72M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | -$5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$7.95M 10-Q · filed 2021-08-05 | -$11.57M derived: sum of 3 quarters · filed 2022-02-28 | $4.98M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | -$2.21M 10-Q · filed 2021-05-04 | -$5.83M derived: sum of 2 quarters · filed 2022-02-28 | $10.72M derived: sum of 3 quarters · filed 2022-02-28 | $6.70M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | -$3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $12.93M derived: sum of 2 quarters · filed 2022-02-28 | $8.92M derived: sum of 3 quarters · filed 2022-02-28 | $4.90M 10-K · filed 2022-02-28 | $4.86M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $16.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $12.53M derived: sum of 2 quarters · filed 2020-11-05 | $8.51M 10-Q · filed 2020-11-05 | $7.85M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | -$4.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$8.03M 10-Q · filed 2020-08-04 | -$8.70M derived: sum of 3 quarters · filed 2021-03-01 | -$12.07M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | -$4.02M 10-Q · filed 2020-04-28 | -$4.68M derived: sum of 2 quarters · filed 2021-03-01 | -$8.06M derived: sum of 3 quarters · filed 2021-03-01 | -$11.46M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | -$664.34K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$4.04M derived: sum of 2 quarters · filed 2021-03-01 | -$7.44M derived: sum of 3 quarters · filed 2021-03-01 | -$8.55M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$6.78M derived: sum of 2 quarters · filed 2019-11-04 | -$7.88M 10-Q · filed 2019-11-04 | $49.04M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | -$3.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$4.51M 10-Q · filed 2019-08-05 | $52.42M derived: sum of 3 quarters · filed 2019-08-05 | |||||
| 2018-03-31 | -$1.11M 10-Q · filed 2019-05-09 | $55.82M derived: sum of 2 quarters · filed 2019-05-09 | ||||||
| 2017-12-31 | $56.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $51.92M 10-K · filed 2019-03-26 | ||||||
| 2017-09-30 | -$5.01M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |